SCHEMBL1089720

SCHEMBL1089720

CCN(CC)CCCNc1nc(N2CCCC2)c2ccccc2n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX1 Q96LB2 1/20 0.58
CACNA2D1 P54289 1/20 0.53
TOP2A P11388 1/20 0.52
POLB P06746 3/20 0.50
BCHE P06276 2/20 0.50
KMT2A Q03164 4/20 0.48
LMNA P02545 4/20 0.48
MAPT P10636 4/20 0.48
MEN1 O00255 3/20 0.48
HTT P42858 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
RECQL P46063 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
ALDH1A1 P00352 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
HPGD P15428 2/20 0.48
ACHE P22303 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1088522 0.99 MRGPRX1 (0.57) MRGPRX1CACNA2D1TOP2APOLBBCHE
SCHEMBL1088774 0.99 MRGPRX1 (0.57) MRGPRX1CACNA2D1TOP2APOLBBCHE
SCHEMBL1090009 0.99 MRGPRX1 (0.57) MRGPRX1CACNA2D1TOP2APOLBBCHE
SCHEMBL1088370 0.93 MRGPRX1 (0.60) MRGPRX1CACNA2D1POLBKMT2ALMNA
SCHEMBL1089537 0.92 MRGPRX1 (0.59) MRGPRX1CACNA2D1POLBKMT2ALMNA
SCHEMBL1089378 0.92 MRGPRX1 (0.59) MRGPRX1CACNA2D1POLBKMT2ALMNA
SCHEMBL1089154 0.92 MRGPRX1 (0.59) MRGPRX1CACNA2D1POLBKMT2ALMNA
SCHEMBL1089423 0.89 MRGPRX1 (0.58) MRGPRX1POLBBCHEKMT2ALMNA
SCHEMBL1090567 0.88 MRGPRX1 (0.60) MRGPRX1TOP2APOLBKMT2ALMNA
SCHEMBL1088871 0.88 MRGPRX1 (0.57) MRGPRX1POLBBCHEKMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-06-21 US disclosed
US-8153625-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-04-10 US disclosed
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2010-09-02 US disclosed
US-7759336-B2 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2010-07-20 US disclosed
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2007-07-19 US disclosed
EP-1571146-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-09-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100221259-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 MRGPRX1 237/4885CACNA2D1 4056/4885TOP2A 3932/4885
US-20070167459-A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof CXCR4, CXCL12, CXCR3 MRGPRX1 237/4885CACNA2D1 4056/4885TOP2A 3932/4885
US-20120156219-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND MEDICINAL USE THEREOF CXCR4, CXCL12, CXCR3 MRGPRX1 237/4885CACNA2D1 4056/4885TOP2A 3932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.